Every 10-Q that Corbus Pharmaceuticals Holdings, Inc. (CRBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRBP filings page.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing therapies in oncology and obesity, led by CRB-701, a Nectin-4–targeting antibody drug conjugate, and CRB-913, a peripherally restricted CB1 inverse agonist for obesity. For the six months ended June 30, 2026, it reported a net loss of approximately $58.0 million, compared with $34.6 million a year earlier, as research and development expenses rose to $51.0 million, driven by a $10.0 million CRB-701 development milestone to CSPC and higher clinical spending on both CRB-701 and CRB-913.
Cash, cash equivalents and investments totaled approximately $117.9 million at June 30, 2026, and management expects this to fund operations for at least twelve months from the report issuance. The company raised about $9.1 million in Q2 2026 through at-the-market stock sales, with an additional $6.7 million raised after quarter-end. CRB-913 showed a mean 2.9% placebo-adjusted weight loss by Day 14 in an obese Phase 1a cohort, and a 240-patient Phase 1b study completed last visits in August 2026, with data expected in September 2026. CRB-701 has fast track designations in cervical cancer and HNSCC, with a registrational 2L OPSCC study (TEMPO-1) expected to begin enrollment in September 2026; the CRB-601 program has been deprioritized.
Corbus Pharmaceuticals Holdings reported a first-quarter 2026 net loss of $22.97 million, compared with $16.98 million a year earlier, as it advanced its oncology and obesity pipeline. Operating expenses rose to $24.30 million, driven mainly by higher research and development spending.
Research and development expense increased to $19.82 million, largely reflecting Phase 1/2 work on Nectin-4–targeting ADC CRB-701 and Phase 1b obesity study CANYON‑1 for CRB-913. Corbus ended March 31, 2026 with cash, cash equivalents and investments of about $138.2 million, which it expects to fund operations for at least 12 months, supported by a new $300 million shelf registration and remaining capacity under its at-the-market equity program.
Corbus Pharmaceuticals (CRBP) reported Q3 2025 results, highlighting higher R&D spending as clinical programs advanced. The company posted a net loss of $23.3 million versus $13.8 million a year ago, driven by R&D of $20.9 million (up 93%) as CRB-701 and CRB-601 trials expanded and CRB-913 progressed in Phase 1. G&A declined to $3.6 million from $4.7 million.
Liquidity remained solid. Cash, cash equivalents and investments were $104.0 million as of September 30, 2025. Management stated that these resources, together with $73.8 million in net proceeds from recent equity sales and the 2025 public offering, are expected to fund operations for at least twelve months after this report’s issuance. Net cash used in operations was $48.6 million for the nine months.
Subsequent to quarter-end, the company sold 232,279 shares via its Open Market Sale Agreement for net proceeds of $3.6 million and completed a public offering on November 3, 2025, raising gross proceeds of $75.0 million (net $70.2 million). Shares outstanding were 12,534,853 as of September 30, 2025.